Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trial

Lee MJ., Cherrill L-R., Zacharopoulou P., Collins S., Fumagalli M., Falaschetti E., Altaf M., Tipoe T., Godakandaarachi P., Fox J., Uriel A., Clarke A., Loes SK-D., Pett S., Boffito M., Whitlock G., Søgaard OS., Ring K., Mangawa I., Gohil J., Elliott T., Nielsen H., Gunst JD., Orkin C., Sutherland R., Hamzah L., Cicconi P., Taylor GP., Ujetz J., Jahan I., Brown H., Robinson N., Fletcher S., Box H., Seaton KE., Tomaras GD., Ackerman ME., Weiner JA., Kaczynska A., Bittar C., Horowitz J., Nussenzweig MC., Caskey M., Frater J., Fidler S.

DOI

10.1016/s2352-3018(26)00059-7

Type

Journal article

Publisher

Elsevier BV

Publication Date

2026-08-01T00:00:00+00:00

Volume

13

Pages

e527 - e537

Permalink More information Close